AngioDynamics Q4 2020 Earnings Report
Key Takeaways
AngioDynamics reported a decrease in net sales by 18.1% compared to the prior-year quarter, with net sales of $58.3 million. The company's performance was impacted by the deferral of elective procedures associated with COVID-19. Gross margin declined to 51.8%, and the company reported a GAAP loss per share of $4.10, which includes a goodwill impairment. Adjusted loss per share was $0.06. The company is focused on managing through the impacts of COVID-19 and remains focused on its long-term strategy.
Net sales decreased 18.1% compared to the prior-year quarter, totaling $58.3 million.
Gross margin declined to 51.8%, a decrease of 630 basis points year over year.
GAAP loss per share was $4.10, including a goodwill impairment of approximately $4.14; adjusted loss per share was $0.06.
Cash and cash equivalents were $54.4 million as of May 31, 2020.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Geographic Location
Forward Guidance
Due to the uncertainty surrounding the magnitude and duration of the continuing impacts of the pandemic, management will not be providing financial guidance for fiscal year 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income